Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific production - Institute for Cancer Research
Annual report 2014 (pdf format)
The Norwegian Society for Immunology is hosting their annual conference on the Day of Immunology on April 29.
The theme for 2016 is Immunotherapy for Cancer and the event is open for any one interested in the theme.
Program and how to register under "More".
Same, but different? Genetic analysis of five immune mediated diseases reveals molecular taxonomy of chronic inflammation
A genetic analysis recently published in Nature Genetics (journal impact factor 29.35) sheds new light on the high comorbidity between primary sclerosing cholangitis (PSC) and inflammatory bowel disease.
Researchers from four large disease consortia, encompassing hundreds of researchers from 26 countries, joined forces to combine data from studies of their respective diseases, amounting to 52,262 patients and 34,213 healthy controls.
“This study is important because it creates a platform for understanding the molecular make-up of each disease, in the future enabling more specified treatment of chronic inflammatory disease”, says Tom Hemming Karlsen, coordinator of one of the participating consortia.
Article published in Science Translational Medicine showing that cyclodextrin may reduce atherosclerosis attracts worldwide attention
Two OUS researchers - professor Bente Halvorsen from the Research Institute of Internal Medicine, and head physician Mona Skjelland from the Department of Neurology - have together with professor Terje Espevik and post doc Siril Bakke from NTNU participated in a large international research project where they have shown that cyclodextrin may reverse atherosclerosis. The study is run by a German research group led by professor Eicke Latz, and the results were recently published in Science Translational Medicine (journal impact factor 18.54). The research has also received widespread attention from various places, including two highly profiled articles in the major newspaper Wall Street Journal.
(story updated with more links to articles from various news sources, under "More")
Kreftforeningen (The Norwegian Cancer Society) and Helse Sør-Øst (The South-Eastern Norway Regional Health Authority) are in the process of changing criteria and evaluation guidelines for this year's announcements.
To inform about the new procedures an open meeting will be held at the Norwegian Radium Hospital on Friday April 22nd.
Time and place: 13:00-14:00, Auditorium, Institute for Cancer Research, Montebello (K building, Norwegian Radium Hospital)
The Fridtjof Nansen Award of Excellence is awarded to Norwegian researchers, or researchers resident in Norway, who has shown scientific contributions of international significance on a very high level.
Fridtjof Nansen Award for Young Scientists for 2016 is divided between Professor Magne Mogstad at the Department of Economics, University of Chicago, for his outstanding research in the fields of economics and Principal Investigator Kyrre Eeg Emblem from the Intervention Centre at Oslo University Hospital, for his outstanding contribution to medical diagnostics.
The awards are presented by the chairman of The Nansen Foundation and Affiliated Funds, Professor Øyvind Østerud, on the Annual meeting of The Norwegian Academy of Science and Letters on Tuesday 3 May, 2016 at the Grand Hotel, Oslo.
Theodossis Theodossiou and Kristian Berg from the Photochemical internalisation (PCI) group at the Department of Radiation Biology have been funded by the Future and Emerging Technology (FET) program under the Excellent Science section of the Horizon 2020 EU Framework for Research and Innovation. The FET program funded this time 11 projects out of 820 grant applications (1,4 % success rate) and the proposal by Theodossiou and Berg was rated as no. 6. The project receives 3 million Euros together with 3 collaborating academic partners as well as one commercial partner (SME) from UK. The project, named Lumiblast, will be coordinated by Kristian Berg. This is the first time Norway is the coordinator of a FET project.
Apr 25, 2016
Professor Péter Nagy – National Institute of Oncology, Hungary
Apr 19, 2016
New guidelines for "Helse Sør-Øst" and "Kreftforeningen" applications
Apr 19, 2016
Apr 11, 2016
Inst. for Cancer Research
Arv1 promotes cell division by recruiting IQGAP1 and myosin to the cleavage furrow
Cell Cycle, 15 (5), 628-43
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
Subtype-specific micro-RNA expression signatures in breast cancer progression
Int J Cancer (in press)
Novel ESCRT functions in cell biology: spiraling out of control?
Curr Opin Cell Biol, 41, 1-8 (in press)
Regulation of ErbB2 localization and function in breast cancer cells by ERM proteins
Oncotarget (in press)